# E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM

> **NCT03357991** · — · UNKNOWN · sponsor: **Hospital Universitari de Bellvitge** · enrollment: 355 (estimated)

## Conditions studied

- HPV - Anogenital Human Papilloma Virus Infection
- HSIL, High Grade Squamous Intraepithelial Lesions
- Anal Cancer
- Hiv

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03357991
- **Lead sponsor:** Hospital Universitari de Bellvitge
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01-11
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 355 (ESTIMATED)
- **Last updated:** 2017-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03357991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03357991, "E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03357991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*